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Role of LAG-3 in Regulatory T Cells
et al., 2002; Annacker et al., 2000, 2001). However, theyChing-Tai Huang,1,2,4 Creg J. Workman,3,4 Dallas Flies,1
Xiaoyu Pan,1 Aimee L. Marson,1 Gang Zhou,1 also suppress natural immune responses to parasites
(Belkaid et al., 2002) and viruses (Suvas et al., 2003)Edward L. Hipkiss,1 Sowmya Ravi,1 Jeanne Kowalski,1
Hyam I. Levitsky,1 Jonathan D. Powell,1 as well as antitumor immunity induced by therapeutic
vaccines (Sutmuller et al., 2001). Manipulation of TregDrew M. Pardoll,1 Charles G. Drake,1,*
and Dario A.A. Vignali3,* function is therefore an important goal of immunother-
apy since this T cell subset appears central to the bal-1The Sidney Kimmel Comprehensive
Cancer Center ance between immune tolerance and immune respon-
siveness for multiple disease processes.Johns Hopkins Medical Institutions
Baltimore, Maryland 21231 Elucidation of Treg mechanisms and manipulation of
this subset would be greatly facilitated by the identifica-2 Department of Medicine
Chang Gung University School of Medicine tion of Treg-selective cell surface receptors that modu-
late their function. While the transcription factor Foxp3and Hospital
Taiwan 33333 appears to be selectively expressed by thymically de-
rived Tregs (Fontenot et al., 2003; Hori et al., 2003; Khat-China
3 Department of Immunology tri et al., 2003), to date no Treg-specific cell surface
receptors have been described. CD25, GITR (McHughSt. Jude Children’s Research Hospital
Memphis, Tennessee 38105 et al., 2002; Shimizu et al., 2002), and CTLA-4 (Read et
al., 2000), the cell surface receptors commonly used to
mark Tregs, are highly upregulated on effector/memory
cells upon antigen-driven activation and are thereforeSummary
not Treg specific. In order to identify Treg-specific mole-
cules, we performed a differential gene expression anal-Regulatory T cells (Tregs) limit autoimmunity but also
attenuate the magnitude of antipathogen and antitu- ysis of antigen-specific T cells, differentiating to either
effector/memory cells in response to viral infection ormor immunity. Understanding the mechanism of Treg
function and therapeutic manipulation of Tregs in vivo Tregs upon encounter of cognate antigen as a self-
antigen. This analysis revealed that the LAG-3 gene wasrequires identification of Treg-selective receptors. A
comparative analysis of gene expression arrays from selectively upregulated in Tregs. The physiologic role
of LAG-3, an MHC class II binding CD4 homolog, has notantigen-specific CD4 T cells differentiating to either
an effector/memory or a regulatory phenotype re- been clearly elucidated. Several studies have suggested
that LAG-3 may have a negative regulatory functionvealed Treg-selective expression of LAG-3, a CD4-
related molecule that binds MHC class II. Antibodies (Hannier et al., 1998; Huard et al., 1994; Workman et al.,
2002a, 2002b, 2004; Workman and Vignali, 2003). Here,to LAG-3 inhibit suppression by induced Tregs both
in vitro and in vivo. Natural CD4CD25 Tregs express we show that membrane expression of LAG-3 selec-
tively marks induced Tregs, that LAG-3 modulates bothLAG-3 upon activation, which is significantly enhanced
in the presence of effector cells, whereas CD4CD25 the in vitro and in vivo suppressive function of Tregs,
and that ectopic expression of LAG-3 is sufficient toTregs from LAG-3/ mice exhibit reduced regulatory
activity. Lastly, ectopic expression of LAG-3 on CD4 confer regulatory activity.
T cells significantly reduces their proliferative capacity
and confers on them suppressor activity toward ef- Results
fector T cells. We propose that LAG-3 marks regula-
tory T cell populations and contributes to their sup- Induced Tregs with Potent Regulatory Activity
pressor activity. In order to study differences between T cell effector/
memory and tolerance induction, we have utilized adop-
Introduction tive transfer of T cell receptor (TCR) transgenic CD4
T cells (clone 6.5) specific for a model antigen hemagglu-
Regulatory T cells (Tregs) have been recognized as an tinin (HA). In wild-type mice infected with recombinant
important mechanism of immunologic tolerance (re- HA-expressing vaccinia virus (Vac-HA), adoptively trans-
viewed in Curotto de Lafaille and Lafaille [2002], Jonuleit ferred HA-specific 6.5 CD4 T cells differentiate into ef-
and Schmitt [2003], Maloy and Powrie [2001], Sakaguchi fector/memory cells upon encounter with HA. The effector/
et al. [2001], and Shevach [2002]). Either emerging di- memory response is characterized by a typical expansion/
rectly from the thymus or being induced in the periphery, contraction phase and the development of memory mark-
Tregs are typically reported to be CD4CD25 and func- ers. When removed from the adoptively transferred animal,
tion by inhibiting effector T cells. They are important in these effector/memory cells are hyperresponsive to HA
maintaining immune tolerance to limit autoimmunity and in vitro relative to naive 6.5 CD4 T cells as assayed by
in regulating homeostatic lymphocyte expansion (Almeida antigen-specific proliferative response and -interferon
production. This memory response persists for months
after adoptive transfer. In contrast, adoptive transfer of*Correspondence: dario.vignali@stjude.org; drakech@jhmi.edu
4These authors contributed equally to this work. 6.5 CD4 T cells into C3-HA transgenic mice that ex-
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Figure 1. HA-Specific CD4 T Cells Become
Tolerant and Develop Regulatory T Cell Activ-
ity upon Adoptive Transfer into C3-HAhigh
Transgenic Mice
(A) C3-HAhigh transgenic mice express high
levels of HA in various epithelial compart-
ments, with the highest level expressed in
pulmonary epithelia. C3-HAhigh recipients die
4–7 days after adoptive transfer of 2.5  106
HA-specific TCR transgenic (6.5) CD4 T cells
due to pneumonitis associated with a tran-
sient effector phase of activation occurring
prior to development of an anergic pheno-
type. Transfer of smaller numbers of 6.5 CD4
T cells results in less severe pulmonary pa-
thology, and the C3-HAhigh recipients survive
the transfer. Residual 6.5 T cells become
anergic as defined by their inability to pro-
duce -interferon or proliferate to HA antigen
in vitro. Mice receiving a sublethal dose of
6.5 T cells are protected from subsequent
infusion of 2.5  106 naive 6.5 T cells. Thus,
the initial tolerized T cells develop Treg activ-
ity that suppresses lethal pneumonitis in-
duced by the second high dose of 6.5 T cells.
(B) Localization of effector/memory versus
suppressed T cells in C3-HAhigh mice. Naive
6.5 T cells (Thy1.1/1.2) were adoptively
transferred into C3-HAhigh recipients (Thy1.1/
1.2), either in the absence or in the presence
of 6.5 anergic cells/Tregs (Thy1.1/1.2).
Spleens and lungs were harvested 3 days
after adoptive transfer, and Thy 1.1 cells were
stained by immunohistochemistry (Thy1.1 ef-
fector T cells are brown; sections are counter-
stained with hematoxylin). In the absence of
Tregs, T effector cells (brown) are scattered
in the splenic follicles (a) and infiltrate the
pulmonary vessels (b). In the presence of
Tregs, suppressed HA-specific 6.5 T cells
(brown) become sequestered in the splenic
periarteriolar lymphatic sheath (c) and fail to
infiltrate the pulmonary vessels (d).
press HA in multiple epithelial tissues results in tolerance C3-HAhigh mice, which have 1000-fold higher HA expres-
sion than C3-HAlow mice, die within 4–7 days after trans-(Adler et al., 1998, 2000). Similar to the effector/memory
response, there is a rapid expansion/activation phase fer of 2.5  106 6.5 CD4 T cells (Figure 1A). The cause
of death is lethal pulmonary vasculitis due to infiltrationcharacterized by proliferation and expression of effector
cytokines, such as -interferon. However, after the acti- of transgenic 6.5 CD4 T cells in the lung where HA
expression is highest. Adoptive transfer of less thanvation phase, the total HA-specific T cell pool contracts
and residual 6.5 cells fail to produce -interferon or pro- 2.5  105 6.5 CD4 T cells into C3-HAhigh mice causes
pulmonary vasculitis of less severity, and the recipientsliferate in vitro upon antigen stimulation 4–7 days after
adoptive transfer (Adler et al., 2000; Huang et al., 2003). survive (Figure 1A) (Huang et al., 2003). Interestingly, 6.5
CD4 T cells transferred at a sublethal dose acquire aThe extinction of the capacity to produce lymphokines
such as IL-2 and -interferon and to proliferate in re- regulatory phenotype as they are capable of protecting
mice from death upon subsequent infusion of whatsponse to antigen represents the standard operational
definition of the anergic phenotype. would be a lethal dose of 6.5 CD4 T cells in unprotected
C3-HAhigh mice. This in vivo regulatory function is ex-The intensity of the initial in vivo effector phase in
C3-HA mice that precedes tolerance induction is propor- tremely potent, since transfer of as few as 8000 cells
(0.3% of the lethal dose) will completely protect animalstional to the number of 6.5 CD4 T cells adoptively trans-
ferred as well as the expression level of HA antigen from death upon subsequent infusion of 2.5  106 naive
6.5 CD4 T cells. Protection is observed as early as 4in the recipient mice. Thus, C3-HAlow mice tolerate the
transfer of 2.5  106 6.5 CD4 T cells quite well, but days after the initial transfer and remains active up to
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6 months (Figure 1A). Depletion of CD4 T cells, but not
CD8 T cells, before adoptive transfer totally eliminates
the protective effect, thereby defining the Treg pheno-
type of anergized clonotypic 6.5 CD4 T cells.
In unprotected mice, the infiltrating T effector cells
that cause the pulmonary vasculitis are scattered in the
spleen and accumulate around the vessels in the lung
(Figures 1Ba and 1Bb). Suppression of lethal pneumoni-
tis is accompanied by an accumulation of the initial input
(Treg) 6.5 T cells in the lungs and a drastic reduction in
the number of infiltrating T effector cells from the second
infusion (Figure 1Bd). Paradoxically, this results in a
greater cellular infiltration but no death. Instead of accu-
mulating in the lungs, as occurs in the absence of Tregs,
the T effector cells accumulate in the splenic periarterio-
lar lymphatic sheath (Figure 1Bc). Further evidence that
the anergic cells demonstrate Treg function comes from
the finding that they inhibit the activation of cytotoxic
HA-specific CD8 T cells in vivo (data not shown). Elimi-
nation of CD25 T cells prior to the first (protective)
adoptive transfer did not affect the development of
Tregs capable of protecting animals from a subsequent
lethal challenge of 6.5 T cells. Therefore, it is likely that
the Treg phenotype of the initial input T cells was ac-
quired after adoptive transfer as opposed to being a
consequence of naturally occurring Tregs among the
adoptively transferred population. These findings are
highly compatible with the observations of Von Boehmer
and colleagues, who demonstrated that 6.5 CD4 T cells
rendered tolerant after transfer into transgenic mice ex-
pressing HA in the B cell compartment in fact exhibit
Treg function (Jooss et al., 2001). Figure 2. LAG-3 Is Differentially Expressed between Anergic/Treg
and Effector/Memory CD4 T Cells
(A) The differential expression revealed by gene chip analysis wasLAG-3 Is Differentially Expressed on Induced Tregs
confirmed by quantitative real-time RT-PCR. The differential expres-In order to identify genes associated with the anergic/
sion of LAG-3 at early time points (day 2 to day 4) extends to 30
Treg phenotype in our in vivo system, we performed days after adoptive transfer.
Affymetrix chip analysis on purified 6.5 CD4 T cells (B) Cell surface LAG-3 protein levels were assessed by antibody
either after adoptive transfer into nontransgenic recipi- staining. Splenocytes were harvested from C3-HAhigh, wild-type
B10.D2 mice immunized with Vac-HA or wt B10.D2 mice 5 daysents followed by Vac-HA immunization to generate ef-
after i.v. injection with 6.5 Thy1.1 splenocytes. All samples werefector/memory T cells or after transfer into C3-HAhigh
first incubated with whole rat IgG to block Fc receptors and thenmice to generate anergic cells/Tregs. Thy1.1/Thy1.2
stained with an anticlonotypic 6.5 TCR mAb plus streptavidin-APC
congenic 6.5 T cells were purified from Thy1.1/Thy1.2 and LAG-3-PE or an irrelevant rat IgG1-PE control. Cells were gated
Vac-HA-infected wild-type (effector/memory) or C3- on 6.5 T lymphocytes. Isotype control, dashed light gray line; naive
HAhigh (anergic/Treg) recipients with a sequential isola- cells, solid light-gray line; effector/memory cells, solid dark-gray
line; anergic cells/Tregs, solid black line.tion procedure involving MACS column depletion of
CD8 T cells, B cells, and Thy 1.2 T cells followed by
flow cytometric sorting to 95% purity. This protocol
avoids the use of TCR-specific or CD4 coreceptor-spe- time points postadoptive transfer. Many of these genes
represented ESTs with no known function. Among thecific antibodies that could potentially alter TCR- or CD4-
dependent gene expression patterns. genes that had been previously identified, LAG-3 was
among the most differentially expressed in anergic/TregRNA was isolated from naive 6.5 CD4 T cells as the
day 0 sample. RNA was also isolated from 6.5 CD4 populations relative to effector/memory populations.
This result was subsequently validated by quantitativeT cells at days 2, 3, and 4 postadoptive transfer for chip
analysis. HA-specific T cells show increasing unrespon- RT-PCR analysis with a LAG-3 primer-probe pair for
various time points extended to 1 month postadoptivesiveness to in vitro stimulation from days 2–4. This devel-
opment of anergy correlates with the acquisition of sup- transfer. After a minimal initial increase in the effector/
memory cells, LAG-3 expression returns to baseline bypressive activity in in vitro suppression assays (data
not shown). Genes that were differentially expressed 20 days postadoptive transfer. In striking contrast,
LAG-3 expression increases 20- to 50-fold over the firstbetween anergic/Treg populations and effector/memory
populations were ranked according to an algorithm that 5 days in anergic cells/Tregs and remains high over the
subsequent 4 week analysis (Figure 2A). In contrast,summed their differential expression from days 0–4. A
surprisingly large number of genes were selectively acti- levels of Foxp3, GITR, and CTLA-4 showed modest in-
creases (1.5- to 4-fold) that were similar in both effector/vated in anergic/Treg populations even at these early
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memory cells and the induced anergic cells/Tregs over
the first 4–5 days (data not shown).
Cell surface expression of LAG-3 on populations of
anergic/Treg 6.5 CD4 T cells relative to effector/mem-
ory 6.5 CD4 T cells was then analyzed with an anti-
LAG-3 monoclonal antibody (Workman et al., 2002b).
While there are very low levels of LAG-3 staining on
effector/memory cells, the majority of anergic cells/
Tregs from C3-HAhigh transgenic mice display moderate
to high levels of LAG-3 staining, correlating with the
gene expression results (Figure 2B).
LAG-3 Is Required for Maximal Treg
Function In Vitro
To determine whether LAG-3 has a direct role in regulat-
ing suppression by induced Tregs, we first determined
whether anti-LAG-3 antibodies could block the ability
of LAG-3-expressing cells to suppress the in vitro prolif-
erative responses of naive HA-specific CD4 6.5 TCR
transgenic T cells. Anti-LAG-3 antibodies at concentra-
tions as low as 2 g/ml inhibit suppression by Treg 6.5
CD4 T cells in this in vitro assay system (Figure 3A).
Over the 2 day assay period, anti-LAG-3 antibodies did
not affect proliferative responses of 6.5 T cells stimu-
lated in the absence of Tregs, confirming that the effect
of anti-LAG-3 antibodies was indeed on the Tregs and
not the effector cells (data not shown). In order to directly
assess the effect of the induced Tregs on responder
T cell proliferation, a similar assay was performed with
CFSE-labeled naive 6.5 T cells. Flow cytometry was
used to determine the percentage of cells with reduced
CFSE fluorescence (CFSElo), which would be indicative
of proliferation. Our experiments show that titration of
the anti-LAG-3 antibody results in a progressive reduc-
tion in Treg activity as indicated by a reciprocal increase
in the percentage of CFSElo cells, whereas the isotype
control had no effect (Figure 3B). Although the anti-
LAG-3 antibody was clearly able to block a significant
proportion of the suppressor activity at low Treg num-
bers, the effect was more limited at high Treg numbers
(Figure 3C). This is not surprising as it is likely that Tregs
utilize multiple molecules to mediate suppression, and
these cells appear to have strong regulatory potential.
The ability of anti-LAG-3 antibodies to block in vitro
suppression by Tregs demonstrates that LAG-3 is not
simply a Treg-selective marker but is a molecule that is
required for maximal Treg activity.
C3-HA recipients. On day 4 after adoptive transfer, CD4 Thy1.1
T cells (Treg) were purified by FACS sorting. Tregs were mixed at
a ratio of 1:50 with naive CFSE-labeled HA-specific Thy1.2 CD4
responder T cells in the presence of increasing concentrations of
anti-LAG-3 antibody (circles) or isotype control (triangles). After 60
hr, cells were harvested and analyzed. Division of responder cells
Figure 3. Anti-LAG-3 Antibodies Block In Vitro Treg Activity was determined with the method of Lyons (Lyons, 2000) and the
software package FlowJo (Tree Star Inc, Ashland, OR). Dashed line,(A) Monoclonal anti-LAG-3 antibody added to the in vitro suppres-
sion assay at a concentration of 2g/ml totally reverses the suppres- no Tregs (responder cells only). Mean  RMS (Root Mean Square)
error for triplicate wells is shown.sion of naive 6.5 CD4 T cell proliferation in vitro by 6.5 CD4
suppressors at a suppressor:responder ratio of 1:25. Dashed line, (C) Tregs were isolated as above and cocultured at increasing num-
bers with naive CFSE-labeled HA-specific Thy1.2 CD4 responderno Tregs (suppressors).
(B) T cells with regulatory function (Treg) were induced by adoptive T cells in the presence of anti-LAG-3 or isotype control antibody
(30 g/ml). Mean  RMS error for triplicate wells is shown.transfer of 2.5  106 HA-specific Thy1.1 CD4 T cells to Thy1.2
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LAG-3 Is Required for Induced Treg Activity In Vivo
We next evaluated the role of LAG-3 in modulating in vivo
Treg function by determining whether administration of
anti-LAG-3 antibodies could block suppression of lethal
pneumonitis by Tregs in C3-HAhigh mice. C3-HAhigh mice
were pretreated with 8000 (sublethal dose) 6.5 CD4
T cells followed by a subsequent dose of 2.5  106
naive 6.5 CD4 T cells 4 days after the first transfer. As
described above, Tregs have already developed at this
point. Anti-LAG-3 antibody (200 g) was administered
i.v. together with the subsequent challenge of 2.5  106
6.5 cells, and another 200 g was given 2 days later.
This antibody treatment totally eliminated the in vivo
suppressive activity of the Tregs, and the mice died in
a time frame comparable to the C3-HAhigh mice lethally
challenged without protective sublethal 6.5 pretreat-
ment (Figure 4A). On the contrary, mice with established
Tregs treated with isotype control antibody (Rat IgG1)
or no antibody survived subsequent challenge with 2.5
106 naive 6.5 T cells. Importantly, parallel control experi-
ments clearly show that the anti-LAG-3 antibody does not
deplete the protective Thy1.1 6.5 T cells in vivo. These
cells are readily detected ex vivo by staining with an
anti-rat IgG1 antibody, which binds to the in vivo anti-
LAG-3 antibody-coated Tregs (see Supplemental Figure
S1 at http://www.immunity.com/cgi/content/full/21/4/
503/DC1/). Furthermore, we saw no reduction in the per-
centage of Thy1.1 cells in the anti-LAG-3-treated mice
compared with the untreated controls (data not shown).
An alternate possibility was that the anti-LAG-3 anti-
bodies were hyperactivating the T cells in the challenge
population such that they overcame the inhibitory ef-
fects of the Tregs. To rule out this possibility, we asked
whether in vivo administration of anti-LAG-3 antibodies
together with a dose of 6.5 T cells just below the lethality
threshold would cause lethality in the absence of a pre-
established Treg population. We therefore administered
2.5  105 6.5 CD4 T cells (the maximal dose that will
not cause lethality) or 8.0 105 6.5 CD4 T cells (roughly
50% lethality between 7 and 14 days after transfer) into
C3-HAhigh mice together with anti-LAG-3 antibodies or
isotype control. Our data clearly show that the anti-
LAG-3 treatment did not render the 2.5  105 6.5 CD4
T cell dose lethal nor did it enhance the partial lethality
of the 8.0  105 6.5 CD4 T cell dose (Figure 4B). In
summary, these data confirm that the anti-LAG-3 anti-
body prevents protection by blocking LAG-3-mediated
Treg function rather than mediating their deletion or
promoting lethality mediated by the effector population.
ate the subsequent lethal challenge (protection  LAG-3). In con-
Figure 4. In Vivo Anti-LAG-3 Antibody Treatment Blocks 6.5 CD4 trast, treatment with isotype control antibody rat IgG1 could not
Treg-Mediated Protection from Lethal Pulmonary Vasculitis eliminate the in vivo suppression (protection control Ab). A represen-
(A) C3-HAhigh mice pretreated with 8000 6.5 CD4 T cells survived tative experiment (three to five animals per group) of five is shown.
subsequent challenge with 2.5  106 6.5 CD4 T cells given 4 days (B) Anti-LAG-3 mAb does not hyperactivate naive 6.5 CD4 T cells
after the initial transfer establishment of Treg population (protection in the absence of Tregs. C3-HAhigh mice received either 2.5  105
only). Without the sublethal pretreatment, the C3-HAhigh recipients (sublethal dose) or 8  105 (partial lethality between 7 and 14 days
died 4–6 days after lethal challenge (no protection). Monoclonal after transfer) naive 6.5 CD4 T cells in combination with anti-LAG-3
anti-LAG-3 antibody (200 g) was given i.v. to the C3-HAhigh mice antibody, control rat IgG1, or no antibody. No lethality was observed
with the lethal dose of 6.5 T cells 4 days after they were pretreated with the anti-LAG-3 antibody infusions at the 2.5  105 dose,
with 8000 6.5 CD4 T cells, and another dose of 200 g was given whereas lethality at the 8  105 dose was not affected by anti-
2 days later. Anti-LAG-3 antibody-treated mice could no longer toler- LAG-3 antibody.
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Figure 5. LAG-3 Is Expressed on Natural
CD4CD25 Tregs and Is Required for Maxi-
mal Natural CD4CD25 Treg Function
(A) Natural CD4CD25 Tregs have higher lev-
els of LAG-3 mRNA expression compared to
their CD4CD25 counterparts. CD4CD25
and CD4CD25 T cells were purified from
wild-type BALB/c lymph nodes. CD4CD25
T cells, the population documented to con-
tain natural regulatory T cells, have signifi-
cantly higher mRNA levels for CD25 and
LAG-3, as well as for CTLA-4, GITR, and
Foxp3, as compared to the CD4CD25 cells
(expression of each mRNA in the CD4CD25
subset was normalized to a value of one).
(B) LAG-3 expression (Mean Fl) was deter-
mined on CD4CD25 Tregs that were sorted
from BALB/c spleens and activated with anti-
CD3 antibody (5 g/ml) and APCs in the ab-
sence or presence of increasing numbers of
CD4CD25 responder T cells.
(C) Expression of LAG-3 on CD4CD25
T cells after activation with (bold line) or with-
out (thin line) CD4CD25 T cells present at
a ratio of 1:2 (Treg:responder). The shaded
histogram represents the negative staining
control. The data are representative of four
experiments.
(D) Sorted CD4CD25 T cells from BALB/c
mouse lymph nodes were used as suppres-
sors and CD4CD25 T cells as responders
in an in vitro suppression assay (suppres-
sor:effector ratio of 1:25) with anti-CD3 anti-
bodies (0.5 g/ml) as the T cell stimulus. Anti-
LAG-3 antibodies at the concentration of 50
g/ml reverse the in vitro suppression of nat-
ural CD4CD25 regulatory T cells, whereas
isotype control antibody does not. Dashed line, no Treg suppressors. Irradiated (3000 rads) BALB/c splenocytes were used as APC.
(E) CD4CD25 T cells were positively sorted from spleens of OT-II.LAG-3/ and OT-II.LAG-3/ mice. The sorted T cells were mixed at different
ratios with irradiated (3000 rads) C57BL/6 APC, naive CD4CD25 OT-II.LAG-3/ T cells (2.5  104 cells/well), and various concentrations of
OVA 326–339 peptide. The number of Tregs required to achieve 50% suppression of the responders was determined at each antigen
concentration. The data represent the mean of three individual experiments. The percentage of CD25CD4 Tregs that are OT-II (V2V	5)
is 52.3%  8.1% in wild-type mice and 56.7%  3.8% in LAG-3.KO mice (mean of four mice per genotype).
(F) A standard Treg proliferation assay was performed with a titration of CD4CD25 T cells from OT-II.LAG-3/ and OT-II.LAG-3/ mice in
the presence of APCs, CD4CD25 OT-II.LAG-3/ T cells, and a high peptide concentration (7.5 g/ml).
LAG-3 Is Expressed by Natural Tregs and Is Required APCs induced significant levels of LAG-3, which also
occurred in the presence of MHC class II/ APCsfor Maximal Regulatory Activity
Taken together, these data confirm an important role (Figures 5B and 5C, and data not shown). Interestingly,
coculture of Tregs with anti-CD3-stimulated naivefor LAG-3 in mediating suppressor function of induced
Tregs. Given that the relationship between induced CD4CD25 T cells induced a 2-fold increase in LAG-3
expression, suggesting that the presence of effectorTregs and natural Tregs remains unclear, it was of inter-
est to see whether the LAG-3 message was expressed T cells may enhance their LAG-3-mediated regulatory
activity. It is noteworthy that this increase occurred inselectively in CD4CD25 T cells from wild-type mice.
LAG-3 mRNA (along with CTLA-4, Foxp3, and GITR a dose-dependent manner (Figure 5B).
To directly evaluate the role of LAG-3 in the regu-mRNA) is indeed selectively expressed in CD4CD25
cells compared with CD4CD25 cells (Figure 5A). Para- latory function of natural Tregs, we asked whether
anti-LAG-3 antibodies could inhibit in vitro suppressiondoxically, we could not detect any LAG-3 protein on the
cell surface of CD4CD25 T cells directly ex vivo. This mediated by purified CD4CD25 cells. As shown in
Figure 5D, CD4CD25 Treg activity is blocked by anti-observation was consistent with our previous finding
that significant amounts of LAG-3 mRNA are detectable LAG-3 antibodies. Finally, we assessed whether natural
CD4CD25 Tregs from LAG-3/ OT-II TCR transgenicin the splenic red pulp, but the percentage of LAG-3
splenocytes is less than 2% (Workman et al., 2002b). mice have comparable regulatory activity to those de-
rived from wild-type OT-II transgenic mice. In theseInterestingly, LAG-3 possesses a rather long 5
 untrans-
lated sequence that is rich in CT and GT repeats, which experiments, we assessed the influence of both Treg
number and antigen dose. The data are expressed ascould play a role in posttranscriptional regulation of
gene expression (Mastrangeli et al., 1996). However, the number of Tregs required to give 50% suppression.
At low peptide concentrations, where Tregs can com-stimulation of CD4CD25 Tregs with anti-CD3 and
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fortably control CD4CD25 T cell proliferation, LAG- Thy1.1GFP-transduced cells in a standard Treg assay
as described above. The percentage of Thy1.2 T cells3/ and wild-type Tregs have equivalent suppressive
capacity. However at high peptide concentrations, with reduced CFSE expression (two or more divisions,
CFSElo) was determined by flow cytometry. Some reduc-where maximal Treg activity is obligatory, 2.6 times as
many LAG-3/ versus wild-type CD4CD25 Tregs are tion in the percentage of CFSElo cells was seen with
increasing numbers of GFP or LAG-3.Y73FCY/GFP-required to control CD4CD25 T cell proliferation (Fig-
ures 5E and 5F). Taken together, these data suggest transduced T cells, which is likely due to competition
for peptide-pulsed APC as the control cells in this in-that LAG-3 plays a significant role in suppression medi-
ated by natural, as well as induced, Tregs. stance are also responding (Figure 6C). However, the
percentage of CFSElo cells seen in the presence of
LAG-3-transduced T cells was considerably lower, sug-Ectopic Expression of LAG-3 Confers
gesting that these cells do have a direct effect on theRegulatory Activity
proliferative capacity of naive CD25 6.5 T cells. It shouldThe data presented thus far suggest that LAG-3 is re-
be noted that as the LAG-3-transduced cells proliferatequired for maximal Treg function. However, is it suffi-
poorly (Figure 6A), they are less likely to compete withcient? We performed a series of transduction experiments
the responders for antigen and APC, and thus the reduc-to determine if ectopic expression of LAG-3 on T cells
tion seen is a direct consequence of suppression byconfers regulatory activity. For these experiments, 6.5
the LAG-3-transduced cells. Taken together, these dataCD4 T cells were first depleted of any CD25 natural
provide direct evidence that confirms the functional roleTregs and then transduced with MSCV-based retrovirus
of LAG-3 in suppression. Interestingly, LAG-3 transduc-encoding either GFP alone, GFP  wild-type LAG-3, or
tion did not induce other genes associated with Tregs,GFP  a mutant LAG-3.Y73FCY that has substantially
including Foxp3, CD25, CD103, and GITR (data notreduced affinity for MHC class II and cannot mediate
shown). Likewise, we have not seen any induction ofdownstream signaling (Workman et al., 2002a). After a
LAG-3 after Foxp3 transduction. This result, together10 day rest period, essentially no endogenous LAG-3
with the lack of significant differential expression ofstaining was observed on GFP CD4 6.5 T cells trans-
Foxp3, CD25, CD103, and GITR between 6.5 T cellsduced with the MSCV-GFP retrovirus, whereas high lev-
differentiating to effector/memory versus anergic/Tregels of LAG-3 staining were observed on GFP 6.5 cells
phenotypes suggests that LAG-3 may mediate a distincttransduced with the MSCV-LAG-3/GFP and MSCV-
pathway of regulatory T cell function independent of theLAG-3.Y73FCY/GFP retrovirus.
Foxp3 pathway.We first assessed the effect of LAG-3 expression on
T cell proliferation. GFP cells from each group were
sorted and stimulated with HA110–120 peptide plus APC. Discussion
T cells expressing the nonfunctional LAG-3 mutant or
GFP alone responded comparably. In contrast, substan- These findings identify LAG-3 as a cell surface molecule
selectively upregulated on Tregs that may be directlytially reduced proliferation was seen with LAG-3-trans-
duced 6.5 T cells after peptide stimulation (Figure 6A). involved in mediating Treg function. Given the many
systems in which both natural and induced Treg activityWe next asked if ectopic expression of LAG-3 was suffi-
cient to confer regulatory activity toward naive T cells. has been defined, it remains to be determined whether
LAG-3 is a universal Treg marker or selectively marksGFP cells were mixed at different ratios with APC,
HA110–120 peptide, and naive 6.5 CD4CD25 T cells in a only certain Treg subsets. Our results suggest that in
addition to the induced CD4 Tregs studied here, LAG-3standard Treg proliferation assay. No suppression was
observed with control 6.5 cells expressing GFP alone plays at least some role in mediating suppression by
natural CD4CD25 Tregs. Furthermore, other experi-or the nonfunctional LAG-3.Y73FCY mutant (Figure
6B). In fact, total proliferation was somewhat increased mental data demonstrate a role for LAG-3 in the regula-
tion of homeostatic lymphocyte expansion by naturalas these cells contribute to [3H]thymidine uptake. In
striking contrast, 6.5 cells expressing wild-type LAG-3 Tregs (C.J.W. and D.A.A.V., unpublished data). At this
stage we do not propose that LAG-3 is a “lineagepotently suppressed proliferation of the naive 6.5 cells.
This was a robust and reproducible finding, which was marker” for Tregs, and it remains to be determined, as
is the case for Foxp3, whether LAG-3 is expressed inalso duplicated with nontransgenic T cells stimulated
with anti-CD3 and OT-II TCR transgenic T cells stimu- all cells with regulatory activity. In fact, it is not clear
that Tregs represent a stable lineage or differentiationlated with cognate peptide (data not shown). Furthermore,
this suppression was contact- or proximity-dependent as state capable of promoting tolerance in a noncell-auton-
omous fashion (von Boehmer, 2003). However, our datadetermined in transwell assays (data not shown). Surpris-
ingly, the suppressive capacity of LAG-3 was compara- do suggest that LAG-3 may mark cells with regulatory
activity.ble to that seen in parallel experiments with ectopically
expressed Foxp3. A number of studies have suggested a cell-autono-
mous inhibitory role for LAG-3 (Huard et al., 1994; Work-As these experiments measure the combined prolifer-
ation of the transduced and naive 6.5 T cells, it is formally man et al., 2002b). Given our proposed role for LAG-3 in
Treg function, it might be expected that LAG-3 knockoutpossible that much of the reduced [3H]thymidine uptake
is a consequence of the reduced proliferation of the mice would display multisystem autoimmunity similar
to that seen in Foxp3 knockout or scurfy mice. However,LAG-3-transduced cells. To assess the proliferation of
the effector population directly, naive Thy1.2 CD25 initial studies with LAG-3 knockout mice failed to un-
cover any evidence for overt autoimmunity or hyperim-6.5 T cells were labeled with CFSE and cocultured with
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munity (Miyazaki et al., 1996). Nonetheless, there are
clearly regulatory T cell defects displayed by LAG-3
knockout mice, such as a defect in regulating cellular
homeostasis (C.J.W. and D.A.A.V., unpublished data)
and those detailed in the present study. We are in the
process of reexamining older LAG-3 knockout mice for
more subtle evidence of late-onset autoimmunity as was
observed in PD-1 knockout mice (Nishimura et al., 1999,
2001). It is also conceivable that other regulatory mecha-
nisms might have been enhanced in these mice to com-
pensate for the loss of LAG-3 expression.
As LAG-3 is expressed on Tregs, it provides an excel-
lent potential target for selective manipulation of Treg
activity to treat both cancer and autoimmune disease.
Indeed, our in vivo treatment of mice with anti-LAG-3
completely blocked Treg-mediated protection from le-
thal pulmonary vasculitis. CD25, the gold standard Treg
marker, is induced at high levels in activated cells, as
it is a critical component of the IL-2 receptor complex.
The apparent reason that CD4CD25 cells are enriched
in Treg activity is not because CD25 is specific to Treg
function, but rather, because Tregs are chronically stim-
ulated by continuous encounter with self-antigen in the
periphery. Recently, the TNF receptor superfamily mem-
ber 18 molecule (also called GITR) was demonstrated
to be upregulated on Tregs. Antibodies to GITR have
been reported to inhibit Treg activity both in vivo and
in vitro. However, GITR is equivalently upregulated on
activated T cells and, therefore, is apparently no more
selective as a marker for Tregs than is CD25 (McHugh
et al., 2002; Shimizu et al., 2002). Moreover, there are
numerous reports that CD4CD25 cell populations can
suppress certain immune functions (Annacker et al.,
2001; Apostolou et al., 2002; Curotto de Lafaille et al.,
Figure 6. Ectopic Expression of LAG-3 in 6.5 CD4 T Cells Reduces
Proliferative Potential and Confers Potent Regulatory Activity
6.5 CD4 T cells (6.5tg) were first depleted of any CD25 natural
Tregs and then transduced with MSCV-based retroviral vectors en-
coding either GFP alone, GFPwild-type LAG-3, or GFP a mutant
LAG-3.Y73FCY that has diminished binding to MHC class II and
cannot mediate downstream signaling. After a 10 day rest period,
essentially no endogenous LAG-3 staining was observed on GFP
6.5 CD4 T cells transduced with the MSCV-GFP vector, whereas
high levels of LAG-3 staining were observed on GFP 6.5 cells
transduced with the MSCV-LAG-3/GFP and MSCV-LAG-3.Y73F-
CY/GFP vectors. GFP cells from each group were sorted for
subsequent experiments.
(A) GFP 6.5 T cells were stimulated with HA110–120 peptide at the
concentrations indicated, pulsed with [3H]thymidine on day 2, and
harvested on day 3. The standard deviation of duplicate wells is
shown. Differences observed were very reproducible and data rep-
resentative of four experiments.
(B) Different numbers of GFP 6.5 T cells were mixed with APC, 5
g/ml HA110–120 peptide, and naive 6.5 CD4CD25 cells in a standard
Treg proliferation assay. Data represent the mean  SEM of three
experiments (two for the LAG-3 mutant) performed on separate
occasions. In total, over ten experiments were performed at different
antigen concentrations with comparable results.
(C) Treg assays were set up as in (B) with the following difference:
GFP 6.5 T cells were Thy1.1, and the naive 6.5 CD4CD25 cells
used as responders were Thy1.2 and labeled with CFSE. The per-
cent division of the responders was determined as a percentage of
cells that had undergone at least two divisions compared to the
total percent of responders that had divided in the absence of GFP
Thy1.1 cells. Data are representative of three experiments.
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Experimental Procedures2001; Graca et al., 2002; Shimizu and Moriizumi, 2003;
Stephens and Mason, 2000). More recently, neuropilin-1
Micehas been suggested as a specific marker for CD4CD25
The C3-HA transgenic mice have been previously described (Adler
Tregs (Bruder et al., 2004). However, our comparative et al., 1998, 2000). Further details can be found in the Supplemental
analysis of gene expression array data showed higher Experimental Procedures.
The TCR transgenic mouse line 6.5, which expresses a TCR recog-levels of neuropilin-1 message on the vac-HA activated/
nizing an I-Ed-restricted HA epitope (110SFERFEIFPKE120) (generouslymemory cells than in our anergic/regulatory cells (data
provided by Dr. Harald von Boehmer, Harvard University, Boston,not presented). Lastly, while Foxp3 has been clearly
MA), was backcrossed nine generations onto the B10.D2 geneticshown to be expressed on CD4CD25 Tregs, there is
background. Transgenic mice used for experiments were 8–24
still significant debate over its expression on in vivo- weeks old.
induced Tregs (Apostolou and von Boehmer, 2004; Chen LAG-3/ mice were provided by Yueh-Hsiu Chien (Stanford Uni-
versity, CA) with permission from Christophe Benoist and Dianeet al., 2004; Cobbold et al., 2004). It is noteworthy that
Mathis (Joslin Diabetes Center, Boston, MA) (Miyazaki et al., 1996).the level of LAG-3 expression on in vivo-activated T cells
Genome-wide microsatellite analysis demonstrated that 96% of theis significantly lower than on our in vivo-generated Tregs,
109 genetic markers tested were derived from C57BL/6 micesuggesting that LAG-3 may be a more reliable marker of
(Charles River Laboratories, Troy, NY). For some experiments, these
cells with regulatory potential. Perhaps even more impor- mice were crossed with OT-II TCR transgenic mice (Ovalbumin 326–
tantly, it appears that LAG-3 expression remains high on 339-specific, H-2Ab-restricted) (kindly provided by Stephen Schoen-
berger, La Jolla Institute for Allergy and Immunology, CA, with permis-6.5 CD4 Tregs, while LAG-3 expression decreases
sion from William Heath, Walter and Eliza Hall Institute, Parkville,shortly after activation in effector/memory T cells, indi-
Victoria, Australia) (Barnden et al., 1998).cating that LAG-3 is not simply an activation marker.
All experiments involving the use of mice were performed in accor-However, a detailed side-by-side comparison of marker
dance with protocols approved by the Animal Care and Use Commit-
expression and regulatory potential is clearly needed. tees of the Johns Hopkins University School of Medicine and St.
Our data show that LAG-3 is required for maximal Jude Children’s Research Hospital.
suppressive activity of both natural and induced Tregs.
Antibodies, Staining, and ImmunohistochemistryHowever, is it sufficient? Thus far, the only molecule
Details can be found in the Supplemental Experimental Procedures.shown to confer regulatory activity on activated T cells
is Foxp3 (Fontenot et al., 2003; Hori et al., 2003). Impor-
Adoptive Transfertantly, we have shown here that ectopic expression of
Clonotypic CD4or CD8T cells were prepared from pooled spleens
LAG-3, but not a functionally defective mutant, on CD4 and lymph nodes of 6.5 transgenic mice. Clonotypic percentage
T cells can also confer regulatory activity. We have also was determined by flow cytometry analysis. The activation marker
shown that ectopic expression of LAG-3 significantly CD44 was analyzed to ensure that these clonotypic cells were naive
in phenotype. After washing three times with Hank’s Balanced Saltreduces proliferative potential. Thus, LAG-3 appears to
Solution, an appropriate number of cells were resuspended in 0.2have both intrinsic and extrinsic regulatory activity.
ml of HBSS for i.v. injection through the tail vein.Different mechanisms have been identified for Treg
function in different systems (reviewed in Shevach [2002]).
Enrichment and Purification of In Vivo Primed 6.5 CD4 T Cells
We saw a clear correlation between the expression of With either effector/memory or tolerance induction in vivo after
LAG-3 and IL-10 mRNA in our induced T cells. However, adoptive transfer, the clonotypic percentage of 6.5 CD4 T cells in
it remains to be determined if IL-10 contributes to the the spleens of recipient mice is only 0.2%–5%. Deliberate enrich-
ment and purification is mandatory to obtain enough clonotypicsuppressive activity in our system.
CD4 T cells for further studies, such as for Affymetrix gene chipHow might LAG-3 be involved in the function of Tregs?
analysis. Donor 6.5 T cells were crossed onto a Thy1.1/Thy1.2Our retroviral transduction data and previous studies
background, which allowed for a two-step enrichment and purifica-
infer that signaling through the unique KIEELE motif tion procedure after adoptive transfer into Thy1.1/Thy1.2 recipi-
transduces an antiproliferative signal that controls cell ents. 6.5 CD4 T cells were first enriched by using biotinylated
growth. Identifying molecules that interact with this mo- anti-CD8 (Ly-2, 53-6.7), anti-B220 (RA3-6B2), anti-Thy1.2 (30-H12)
antibodies (antibodies purchased from BD PharMingen, San Diego,tif is clearly a priority. How LAG-3 might mediate extrin-
CA), MACS streptavidin microbeads, and MACS LS separation col-sic T cell regulation is more elusive. LAG-3 signaling is
umns (Miltenyi Biotech, Auburn, CA) to deplete CD8 T cells, B cells,required, suggesting that it may induce the expression
and the recipient T cells (Thy1.2). Since CD4 T cells and CD8
of regulatory cytokines or cell surface molecules. LAG-3 T cells are the only populations bearing Thy1.1 and because CD8
may also interfere with TCR signaling, although our data T cells had been depleted during enrichment, sorting for Thy1.1
suggest that it does not interfere with MHC:CD4 interac- cells with FACSVantage SE cell sorter (BD Biosciences) resulted in
highly purified 6.5 CD4 T cells (95%). This technique avoids the usetion despite its superior affinity. Like Foxp3, the regula-
of TCR-specific or CD4 coreceptor-specific antibodies that couldtory mechanism of LAG-3 remains to be fully elucidated.
potentially alter TCR- or CD4-dependent gene expression patterns.However, our data do suggest that LAG-3 may be an
important contributor to both induced and natural Treg
Gene Chip Analysis, Statistical Ranking, and Quantitative
function. Real-Time PCR Analysis
Lastly, another key question is whether Tregs sup- Details can be found in the Supplemental Experimental Procedures.
press the reactivity of CD4 and CD8 effector cells
In Vitro Suppression Assay for Induced 6.5 Regulatory T cellsthrough direct T-T interactions or through DC intermedi-
Purified naive 6.5 CD4 T cells (responders, 1  104) and 3000-rad-aries. The identification of Treg-selective and functional
irradiated syngeneic B10.D2 splenocytes (antigen-presenting cells,expression of LAG-3, an MHC class II binding molecule,
6  104 for antibody-blocking studies or 1  105 for all other experi-
should provide a new handle on dissecting mechanisms ments) were mixed with different numbers of suppressor 6.5 CD4
and manipulating Treg function for diseases in which T cells and incubated in round bottom 96-well tissue culture plates
with 10 g/ml of HA class II (110SFERFEIFPKE120) peptide (200 lthese cells play an important role.
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total). Forty-eight to 72 hr later, cultures were pulsed with 1 Ci Received: January 7, 2004
Revised: August 2, 2004[3H]thymidine and incubated an additional 16 hr before harvest with
a Packard Micromate cell harvester. Determination of the amount Accepted: August 12, 2004
Published: October 19, 2004of incorporated radioactive counts was performed with a Packard
Matrix 96 direct 	 counter (Packard Biosciences, Meriden, CT). Alter-
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